Neurocrine Biosciences Inc (NBIX)

02:56 AM

Is Neurocrine Biosciences Inc. (NB3) stock a buy for dividend portfolios2025 Big Picture & Technical Entry and Exit Alerts - newser.com

02:56 AM

02:46 AM

Why Neurocrine Biosciences Inc. stock remains resilientPortfolio Performance Report & Real-Time Stock Movement Alerts - newser.com

02:46 AM

Nov 14, 2025

What makes Neurocrine Biosciences Inc. (NB3) stock appealing to growth investors2025 Sector Review & Low Risk High Win Rate Picks - newser.com

Nov 14, 2025

Nov 14, 2025

Can Neurocrine Biosciences Inc. stock weather global recessionEarnings Miss & Community Driven Trade Alerts - newser.com

Nov 14, 2025

Nov 14, 2025

Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyJuly 2025 Fed Impact & Low Drawdown Investment Strategies - newser.com

Nov 14, 2025

Nov 14, 2025

Is Neurocrine Biosciences Inc. stock trading near support levelsJuly 2025 Retail & AI Forecasted Entry and Exit Points - newser.com

Nov 14, 2025

Nov 14, 2025

Can Neurocrine Biosciences Inc. (NB3) stock beat analyst consensusTrade Volume Summary & Consistent Profit Alerts - newser.com

Nov 14, 2025

Nov 14, 2025

How Neurocrine Biosciences Inc. stock responds to policy changesWeekly Profit Report & Consistent Return Strategy Ideas - newser.com

Nov 14, 2025

Nov 13, 2025

Will Neurocrine Biosciences Inc. (NB3) stock boost dividends furtherPortfolio Value Report & Real-Time Volume Analysis Alerts - newser.com

Nov 13, 2025

Nov 13, 2025

Is it time to cut losses on Neurocrine Biosciences Inc.Weekly Trend Recap & Technical Confirmation Alerts - newser.com

Nov 13, 2025

Nov 13, 2025

Is Neurocrine Biosciences Inc. (NB3) stock attractive for dividend growthTake Profit & Risk Controlled Daily Trade Plans - newser.com

Nov 13, 2025

Nov 13, 2025

Measuring Neurocrine Biosciences Inc.’s beta against major indicesPortfolio Risk Summary & Daily Stock Trend Watchlist - newser.com

Nov 13, 2025

Nov 13, 2025

What data driven models say about Neurocrine Biosciences Inc.’s futureJobs Report & Smart Swing Trading Alerts - newser.com

Nov 13, 2025

Nov 13, 2025

How to build a dashboard for Neurocrine Biosciences Inc. stockWeekly Market Summary & Expert Approved Momentum Ideas - newser.com

Nov 13, 2025

Nov 13, 2025

What earnings revisions data tells us about Neurocrine Biosciences Inc.Quarterly Risk Review & Expert Curated Trade Setup Alerts - newser.com

Nov 13, 2025

Nov 12, 2025

Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum - Yahoo Finance

Nov 12, 2025

Nov 12, 2025

What analysts say about Neurocrine Biosciences Inc stockPrice Volatility Patterns & Small Budget Growth - earlytimes.in

Nov 12, 2025

Nov 12, 2025

Neurocrine Biosciences to Present at Upcoming Investor Conferences - Your Wyoming Link

Nov 12, 2025

Nov 12, 2025

Assessing Neurocrine Biosciences After Stock Rises 7.8% and Partnership Expansion News - Yahoo Finance

Nov 12, 2025

Nov 12, 2025

What analysts say about Neurocrine Biosciences Inc NB3 stockSector Performance Review & Free Turn Volatility To Profit - earlytimes.in

Nov 12, 2025

Nov 12, 2025

Neurocrine’s depression candidate fails mid-stage study but analysis continues - The Pharma Letter

Nov 12, 2025

Nov 12, 2025

Neurocrine Biosciences (NBIX): Assessing Valuation After Lead Depression Drug Misses Phase 2 Study Goal - simplywall.st

Nov 12, 2025

Nov 12, 2025

What valuation multiples suggest for Neurocrine Biosciences Inc. stockPortfolio Value Summary & Daily Volume Surge Signals - newser.com

Nov 12, 2025

Nov 12, 2025

Neurocrine Biosciences fails mid-stage study of depression drug - MSN

Nov 12, 2025

Nov 11, 2025

Neurocrine Bio Drug Licensed From Takeda Flunks Mid-Stage Test in Depression - MedCity News

Nov 11, 2025

Nov 11, 2025

Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice - sharewise.com

Nov 11, 2025

Nov 11, 2025

Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile - Benzinga

Nov 11, 2025

Nov 11, 2025

Neurocrine’s Depression Drug Misses In Phase II - Citeline News & Insights

Nov 11, 2025

Nov 11, 2025

Morgan Stanley Lowers Price Target for Neurocrine Biosciences (N - GuruFocus

Nov 11, 2025

Nov 11, 2025

Neurocrine Biosciences' Depressive Disorder Drug Fails to Meet Primary Goal in Phase 2 Study - MarketScreener

Nov 11, 2025

Nov 11, 2025

Neurocrine’s depression drug fails to meet primary endpoint in phase 2 - Investing.com Nigeria

Nov 11, 2025

Nov 10, 2025

Neurocrine’s depression drug fails to meet primary endpoint in phase 2 By Investing.com - Investing.com South Africa

Nov 10, 2025

Nov 10, 2025

Neurocrine chalks up a depression drug failure - BioPharma Dive

Nov 10, 2025